Skip to main content

Table 1 Demographic, clinical and laboratory characteristics of patients in the study group

From: Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations

Variable   AMLDNMT3A/FLT3/NPM1 Other* P-value
Age (years) Median 56.00 62.00 0.025
  Range 29-81 21-91  
Sex Female (%) 23 (65.7) 67 (46.9) 0.045
  Male (%) 12 (34.3) 76 (53.1)  
BM Blast % (range) Median 83.5 (29-98) 71.0 (20-99) <0.001
Hemoglobin g/dL (range) Median 9.6 (6-13) 9.3 (6-14.3) 0.683
WBC 103/μL (range) Median 50.9 (0.1-298) 19.0 (0.3-297) 0.006
Monocytes 103/μL (range) Median 4.0 (0-76) 5.0 (0-73) 0.960
Platelets 103/μL (range) Median 45.0 (7-218) 50.0 (8-1069) 0.397
PB Blast % (range) Median 46.0 (0-99) 23.0 (0-99) 0.191
CG Risk Group % Intermediate 91.4 80.4 0.168
  Poor 2.9 14.0  
CN-AML%   87.5 67.4 0.024
  1. *Includes: All mutation groups other than AMLDNMT3A/FLT3/NPM1.
  2. Abbreviations: AML acute myeloid leukemia, BM bone marrow, PB peripheral blood, WBC white blood cell count, CG cytogenetic, CN-AML cytogenetically normal AML.
  3. Bold font indicates parameters with significant differences between groups.